Progesterone Luteal Support in Unexplained Infertility Management
NCT07738068
Female Infertility, Female Urogenital Diseases
View Trial DetailsNCT Number: NCT06503952
A recent randomised controlled trial and previous large cohort studies have shown that the uterine immune environment is a crucial element in improving the performance of Assisted Reproductive therapy (ART). As previous studies mixed Day-3, Day-5, single or doble embryo transfer, the clear influence of the endometrial environment on the embryo itself and its type of transfer (fresh or freeze thawed) need further investigation.
To complement previous studies, the present matched- pair study aims to select the population who exclusively received a single Day-5 embryo transfer (SET) and benefitted of a uterine immune profiling between 1 January 2020 and 30 June 2023 before the SET Day-5.
This population will be matched to a population. who did not have uterine immune profiling in the nine months prior to the single Day 5 embryo transfer between 2018 and 2023.
The matching criteria are the maternal age (+/-1 year), the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and the same type of transfer (IVF, ICSI, frozen transfer) and the same category of expansion of the blastocoel (B1-B2/ B3-B4/ B5-B6).
The primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations
Trial opening soon.
Get Notified18 year–41 year
Female
Observational
Hopital des Bluets- centre d'assistance medicale à la procreation, Paris, Ile de, France
The PRECONCEPTIO software will be used to extract all the uterine immune profiles carried out between January 2020 and June 2023 for patients attending the two reproductive centres, Bluets and Diaconnesse.
In parallel, data will be extracted from the MEDIFIRST software selecting all patients who benefited from a single day 5 embryo transfer between January 2018 and March 2024.
The case group represents the selection of patients who had both uterine immune profiling prior to ET and Day 5 single embryo transfer within the nine months following uterine immune profiling.
Each patient in the treated group is matched to patients who had a single Day 5 ET without immune profiling in the nine months prior to ET.
Matching criteria will be maternal age (+/-1year) and, number of previous egg retrievals (including the ones without any transfer) and, number of previous ETs and technique used (IVF, ICSI, frozen embryo transfer) and degree of expansion of blastocoel (B1-B2/B3-B4/B5-B6) to reflect the quality of the embryo transferred The primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations
Impact of the uterine immune profiling on the live birth rate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
For case: Uterine immune profiling followed by a Day-5 fresh SET or day-5 or Day-6 freeze-thawed SET within the nine months following the uterine immune profiling between January 2020 and June 2023.
Will be excluded patients with no SET day-5, with uterine immune profiling more than nine months before, or with no matching pair For control: Blastocyst SET without uterine immune profiling within the year prior the embryo transfer matched to the case group between January 2018 on June 2023
Time frame: 9 months after the ET
Live birth rate following the Day-5 ET between the case and control groups
Time frame: one month after ET
Implantation rate following the Day-5 ET between the case and control groups
Time frame: two weeks after ET
Clinical pregnancy rate after the Day-5 ET between the case and control groups
Time frame: 12 weeks after ET
Ongoing PR after the day-5 ET between the case and control groups
Time frame: 20 weeks after the ET
Miscarriage rate after the Blastocyst SET in the case and the pair-matched group
Contact information is provided by the study sponsor or research team.
Nathalie LEDEE, MD, PhD
CONTACT
Nathalie Lédée, MD, PhD
CONTACT
Matricelab Innove
Other
Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst: a Matched Controlled Study
Acronym: UTIMPROSET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738068
Female Infertility, Female Urogenital Diseases
View Trial DetailsNCT07725458
Behavior, Genital Diseases
Tampa, Florida, United States
View Trial DetailsNCT07691073
Genital Diseases, Infertility
Sabadell, Barcelona, Spain
View Trial DetailsNCT07684963
Cardiovascular Diseases, Genital Diseases
View Trial Details